MedTrace Logo

Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder

NCT02362529 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2019-05-23

No results posted yet for this study

Summary

The purpose of this study is to determine if translocator protein total distribution volume (TSPO VT) is elevated in major depressive disorder that is not responding to medication and if adding minocycline can affect TSPO VT. Many remain treatment resistant with common antidepressant treatments and the investigators think it may be due to poor targeting of brain pathologies.

Conditions

Interventions

DRUG

Minocycline

50 mg and 100 mg capsule, oral administration

DRUG

Placebo

Lactose monohydrate in identical gel capsules to minocycline, oral administration.

DRUG

Celecoxib

100 mg and 200 mg capsules, oral administration.

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    lead OTHER

Principal Investigators

  • Jeffrey H Meyer, MD, PhD · Centre for Addiction and Mental Health; University of Toronto

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02362529 on ClinicalTrials.gov